Mirum presents liver disease drug data at AASLD conference Nov 7, 2025 08:11AM
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting® Nov 7, 2025 08:10AM
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Nov 4, 2025 04:01PM
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 Oct 28, 2025 04:02PM
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Aug 6, 2025 04:01PM
View Older Stories

Jul 30, 2025 04:01PM Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
May 19, 2025 08:52AM Mirum Pharmaceuticals, Inc. (MIRM) appoints Doug Sheehy as CLO
May 19, 2025 08:30AM Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
May 14, 2025 04:05PM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
May 9, 2025 08:30AM Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL
May 7, 2025 04:01PM Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Apr 30, 2025 08:30AM Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
Apr 28, 2025 08:30AM Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
Apr 14, 2025 08:32AM Mirum Pharmaceuticals' (MIRM) LIVMARLI in tablet form receives FDA approval
Apr 14, 2025 08:30AM Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
Mar 27, 2025 08:33AM Mirum (MIRM) partner Takeda receives LIVMARLI approval in Japan
Mar 27, 2025 08:30AM LIVMARLI Now Approved in Japan for ALGS and PFIC
Mar 10, 2025 08:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 26, 2025 04:01PM Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Feb 24, 2025 08:30AM Mirum Pharmaceuticals' (MIRM) CTEXLI Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis
Feb 24, 2025 08:30AM Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
Feb 19, 2025 04:04PM Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
Feb 10, 2025 07:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 13, 2025 08:36AM Mirum Pharmaceuticals (MIRM) Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
Jan 13, 2025 08:30AM Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
Jan 10, 2025 06:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 6, 2025 04:04PM Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nov 14, 2024 08:00AM Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
Nov 12, 2024 08:00AM Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 7, 2024 04:30PM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 4, 2024 04:30PM Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Oct 31, 2024 08:30AM Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
Oct 10, 2024 08:30AM Mirum Pharmaceuticals (MIRM) Announces Volixibat Granted FDA Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
Oct 10, 2024 08:30AM Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
Aug 28, 2024 04:01PM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 7, 2024 04:01PM Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Jul 31, 2024 04:30PM Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
Jul 25, 2024 08:35AM Mirum Pharmaceuticals' (MIRM) LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
Jul 25, 2024 08:30AM Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
Jul 8, 2024 08:30AM Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
Jun 28, 2024 08:30AM Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
Jun 17, 2024 08:04AM Mirum Pharmaceuticals' (MIRM) Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
Jun 17, 2024 08:00AM Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
Jun 16, 2024 05:00PM Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
Jun 10, 2024 10:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 6, 2024 09:30AM Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
Jun 5, 2024 04:05PM Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
May 31, 2024 08:31AM Mirum Pharmaceuticals (MIRM) Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
May 31, 2024 08:30AM Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
May 29, 2024 08:32AM Long-Term Data from Mirum’s (MIRM) LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
May 29, 2024 08:30AM Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
May 18, 2024 07:00AM Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
May 10, 2024 07:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2024 04:02PM Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024 04:10PM Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
View Older Stories